Medical Watch Disease & Treatment News

Blood tests (p-tau217/GFAP) to primary care; Biogen diranersen Ph2; Auvelity FDA-approved (76% response); Leqembi subQ; XPro1595; NULISAseq; APOE2; Zervimesine; AI; nanotechnology; synaptic regeneration. New: BMS tau/neuroinflammation; pTau181 age 45 memory link; ALZ-101 vaccine; Lormalzi India; TBI immunomodulation; CSVD vascular driver; Leucettinib-21 DS Ph1; LDLR-LA peptides; single-cell multi-omics and sporadic AD cell models (REST/nuclear defects). Lecanemab/donanemab confirmed first DMTs under ATN framework. GLP-1 brain mechanism insights reinforce semaglutide repurposing. Also new: CAA differences in LBDs (DLB vs PD) inform trial stratification; P. gingivalis drives AD via microglial ferroptosis (NOX4 pathway) – druggable target; NIBS for FTD shows syndrome-specific signals. New: FTL1 protein blockade clears brain plaque and restores memory in aged mice (preclinical target); type 3 diabetes hypothesis gains support from post-mortem data; OLX-07010 tau-targeting oral candidate Ph1a safety clean; FDA drug repurposing initiative prioritizes neurodegeneration; Peppermint smell test as early AD/PD biomarker; circuit utilization framework for episodic memory proposed. Latest: FDA Breakthrough Designation for urine-based AD test (VOCs+ML); cardiac amyloid-AD link suggests heart plaques may precede brain plaques; tau–mitochondrial crosstalk review with multi-omics/AI; 28bio CNS-3D Alzheimer’s model for drug prediction; plasma eMTBR-tau243 + %p-tau217 validated for biological staging in JAMA Neurology. New: Nitric oxide splicing mechanism in AD identified; repurposing trial (atomoxetine, metformin) for AD underway. Lifestyle interventions vs anti-amyloid drugs comparison video highlights multimodal benefits. Also new: BMS publicly commits to diversified Alzheimer's strategy beyond amyloid – tau, inflammation, and symptomatic treatments (Cobenfy for psychosis) – signals pharma shift toward combination approaches. New blood test coverage: Press highlights the JAMA Neurology validation of eMTBR-tau243 + %p-tau217 for staging, reinforcing non-invasive diagnostic momentum. Today: Critical video on anti-amyloid drugs questions amyloid removal alone; biomarker podcast provides clinical guidance on fluid biomarkers. New: Review of GLP-1 RAs and SGLT-2i repurposing for AD/PD confirms biological plausibility but calls for longer trials and biomarker stratification. **This run:** St. Louis researchers (Holtzman, Bateman) receive Bayh-Dole award for PrecivityAD blood test – detects amyloid up to 20 years before symptoms, reinforces early detection and racial equity. GLP-1s may rewire brain regions in teens with hormonal disorder – preliminary but supports semaglutide neuroprotection hypothesis. **Latest:** NICE reconsidering lecanemab/donanemab for NHS under new cost-effectiveness thresholds; ALZpath CEO interview reinforces pTau217 blood test momentum with Roche Elecsys moving to clinical standardization; Alzprotect IND clearance for AZP2006, another AD candidate entering clinic. **New this run:** Two Lancet studies confirm p-tau217 and amyloid blood tests detect Alzheimer's pathology in midlife (avg age 61) with cognitive correlates, reinforcing early detection narrative and potential for preventive trials. **New articles this run:** Amyloid plaque heterogeneity (cored vs diffuse) provides molecular basis for variable anti-amyloid DMT responses; Spinogenix tazbentetol oral synaptic regenerative therapy shows Phase 2a data across ALS, AD, schizophrenia – potential platform therapy. Also: Japanese vitamin K neurogenesis compounds early signal for AD/PD.